

# Administrative Bulletin 21-18

**101 CMR 320.00 Clinical Laboratory Services**

Effective January 25, 2021

**Procedure Code Update**

Pursuant to 101 CMR 320.01(4)(c), the Executive Office of Health and Human Services is updating rates for certain clinical laboratory services related to Coronavirus Disease 2019 (COVID-19). In each case, rates have been set consistent with 100% of Medicare fees. The changes, effective for dates of service on or after January 25, 2021, are as follows.

| **Code** | **Previous Rate** | **Updated Rate** | **Code Description** |
| --- | --- | --- | --- |
| 86408 | I.C. | $42.13 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen |
| 86409 | I.C. | $105.33 | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer |
| 86413 | I.C. | $51.43 | Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative |
| 87426 | $10.94 | $35.33 | Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]) |
| 87428 | I.C. | $63.59 | Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B |
| 87636 | I.C. | $142.63 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique |
| 87637 | I.C. | $142.63 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique |
| 87811 | I.C. | $41.38 | Infectious agent antigen detection by immunoassay with direct optical (i.e., visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) |